ReviewActa pharmacologica Sinica2015
Efficacy-oriented compatibility for component-based Chinese medicine.
Review in Acta pharmacologica Sinica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- The Effects of Elgucare on Degenerated Intervertebral Disc-Induced Low Back Pain and Disc Regeneration: A Clinical Trial.Computational and mathematical methods in medicine · 2021Trial
- FuTCM-PDD: a multi-level information fusion framework integrating KAN modeling and AutoML for phenotype-based drug discovery from Traditional Chinese Medicine.Chinese medicine · 2026Article
- Metabolomics and Mechanistic Approaches Reveal the Synergistic and Attenuating of Rubus chingii Hu on Tripterygium Glycoside Tablets in the Treatment of Rheumatoid Arthritis.Chemistry & biodiversity · 2026Article
- Metabolic difference of potentially toxic components from Psoraleae Fructus and Euodiae Fructus in Sishen formula by different compatibilities and physiologies.Journal of pharmaceutical analysis · 2026Article
- PEBL, a component-based Chinese medicine, reduces virus-induced acute lung injury by targeting FXR to decrease ACE2 levels.Journal of advanced research · 2026Article
- Molecular Compatibility in Chinese Medicine for Cancer Treatment and Drug Development: From Traditional Wisdom to Innovative Therapeutics.Chinese journal of integrative medicine · 2026Article
- Dendrobium and Orchidaceae Plants in Dermatology: A PubMed-Based Bibliometric Analysis and Mechanistic Overview.Clinical, cosmetic and investigational dermatology · 2026Article
- Inhibition Effects of Patchouli Alcohol, Carvacrol, p-Cymene, Eucalyptol and Their Formulations Against Influenza Virus Pneumonia Through TLR4/NF-κB/NLRP3 Signaling Pathway.Chemical biology & drug design · 2025Article
- Drug repurposing in traditional Chinese medicine: from empirical wisdom to modern therapeutic strategies.Frontiers in pharmacology · 2025Review
- Antidepressant Properties of a Four-compound Cocktail Identified from Si-Ni-San by HIF-1 Pathway Modulation.Current computer-aided drug design · 2025Article
- An active ingredient from the combination of Corydalis Rhizoma and Paeoniae Radix Alba relieves chronic compression injury-induced pain in rats by ameliorating AR/Mboat2-mediated ferroptosis in spinal cord neurons.Frontiers in pharmacology · 2025Article
- Current Treatment Methods for Charcot-Marie-Tooth Diseases.Biomolecules · 2024Review
- Chinmedomics: a potent tool for the evaluation of traditional Chinese medicine efficacy and identification of its active components.Chinese medicine · 2024Review
- Integration of transcriptomics and metabolomics reveals toxicological mechanisms of ZhuRiHeng drop pill in the 180-day repeated oral toxicity study.Frontiers in pharmacology · 2024Article
- A Comprehensive Review of Coptidis Rhizoma and Magnoliae Officinalis Cortex Drug Pair and Their Chemical Composition, Pharmacological Effects and Pharmacokinetics Analysis.Drug design, development and therapy · 2024Review
- Danshen-Shanzha formula for the treatment of atherosclerosis: ethnopharmacological relevance, preparation methods, chemical constituents, pharmacokinetic properties, and pharmacological effects.Frontiers in pharmacology · 2024Review
- Efficacy analysis and research progress of complementary and alternative medicines in the adjuvant treatment of COVID-19.Journal of biomedical science · 2023Review
- Reveal the Patterns of Prescriptions for Recurrent Respiratory Tract Infections' Treatment Based on Multiple Illustrious Senior Traditional Chinese Medicine Practitioners.Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Mass spectrometry-based metabolomics for discovering active ingredients and exploring action mechanism of herbal medicine.Frontiers in chemistry · 2023Review
- Traditional Chinese medicine active ingredients-based selenium nanoparticles regulate antioxidant selenoproteins for spinal cord injury treatment.Journal of nanobiotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-target drugs have not achieved satisfactory therapeutic effects for complex diseases involving multiple factors. Instead, innovations in recent drug research and development have revealed the emergence of compound drugs, such as cocktail therapies and "polypills", as the frontier in new drug development. A traditional Chinese medicine (TCM) prescription that is usually composed of several medicinal herbs can serve a typical representative of compound medicines. Although the traditional compatibility theory of TCM cannot be well expressed using modern scientific language nowadays, the fundamental purpose of TCM compatibility can be understood as promoting efficacy and reducing toxicity. This paper introduces the theory and methods of efficacy-oriented compatibility for developing component-based Chinese medicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.